摘要
胰高血糖素样肽1是重要的肠促胰岛素成员之一,对2型糖尿病及肥胖症有显著疗效。其类似物抗二肽基肽酶Ⅳ的降解,已开始应用于临床,这些类似物作为新的糖尿病和肥胖症的治疗药物,将会有重要的应用前景。
Glucagon-like peptide-1 is one of the most important members of incretin, which has an unusual therapeutic potential in type 2 diabetes mellitus and obesity. Its analogues are resistant to dipeptidyl peptidase Ⅳ hydrolysis and begin to be used clinically. These preparations may have important application perspective as new therapeutic agents in the treatment of diabetes mellitus and obesity.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2005年第3期288-291,共4页
Chinese Journal of Endocrinology and Metabolism
